Why No NDA Has Been Filed Yet An NDA cannot be filed until Phase 3 is complete
The PatchMD Berberine Patch is specifically formulated to complement these medications with targeted nutrients that help support metabolism, glucose regulation, fat-burning pathways, and overall wellness
By engaging GIP, GLP-1, and GCG receptors, it aims to suppress appetite, enhance glycemic control, and promote energy expenditure
It mimics two hormones, GLP-1 and glucose-dependent insulinotropic polypeptide (GIP)
Typical Weekly Pattern During This Phase Weight loss: 0-0.5 pounds weekly average, with frequent plateau weeks Appetite: Remains suppressed compared to baseline but increased compared to weeks 8-28 Energy: Stable at levels established in weeks 25-36 Side effects: Essentially none
And one just one example of the ecosystem is noting that our vagus nerve, so from our brain via our vagus nerve delivers messages to the gut for the release of these hormones that are then secreted
